Alzheimer’s Disease Drugs Aduhelm, Leqembi May Cause Brain Shrinkage: Study
A new study warns that Aduhelm and Leqembi, new Alzheimer's disease drugs, may cause brain shrinkage which accelerates the condition instead of treating it.
A new study warns that Aduhelm and Leqembi, new Alzheimer's disease drugs, may cause brain shrinkage which accelerates the condition instead of treating it.
A House report raises questions about the overly-close relationship between the FDA and Biogen, which led to approval of the Alzheimer's disease drug Aduhelm, despite significant evidence the drug did…
A new study warns that the FDA fails to rely on previous experience in dealing with the approval of drugs with questionable effectiveness, which could erode public trust.
Two powerful House committee chairs are calling on the FDA to provide a raft of information on how and why it approved the controversial new Alzheimer's drug Aduhelm.
Doctors say they are losing confidence in new drugs approved by the FDA following a number of recent decisions and perceptions of an overly close relationship with the pharmaceutical industry.
The FDA's Acting Commissioner has asked the Office of the Inspector General to investigate the agency's controversial decision to approve the new Alzheimer's disease drug, Aduhelm, following a wave of…
Two members of an FDA advisory committee have resigned in protest over the approval of a new Alzheimer's disease drug, which many critics say shows no evidence of actually being…
The FDA faces criticism for the rushed approval of a new Alzheimer's disease drug, which its own advisors say has not been shown to be effective.